Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Discontinuation of long-term effective entecavir or tenofovir therapy in patients with HBeAg-negative chronic hepatitis B

X
Trial Profile

Discontinuation of long-term effective entecavir or tenofovir therapy in patients with HBeAg-negative chronic hepatitis B

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entecavir (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DARING-B
  • Most Recent Events

    • 13 Nov 2018 Results (n=58) assessing the kinetics of serum HBcrAg in non-cirrhotic Chronic Hepatitis B patients who discontinued long-term effective ETV/TDF therapy, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 13 Nov 2018 Results examining predictors of HBsAg loss and retreatment in non-cirrhotic Chronic Hepatitis B patients who discontinued long-term effective ETV/TDF therapy, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 14 Apr 2018 Results presented at The International Liver Congress 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top